EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter controlled trial of mycophenolate mofetil vs intravenous cyclophosphamide as induction therapy for severe lupus nephritis



Multicenter controlled trial of mycophenolate mofetil vs intravenous cyclophosphamide as induction therapy for severe lupus nephritis



Journal of the American Society of Nephrology 14(Abstracts Issue): 38A, November




(PDF 0-2 workdays service: $29.90)

Accession: 035349757

Download citation: RISBibTeXText



Related references

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 10(5): 504-510, 2005

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis and Rheumatism 62(1): 211-221, 2010

AB0618Comparison of mycophenolate mofetil and intravenous cyclophosphamide as induction therapy in korean patients with lupus nephritis. Annals of the Rheumatic Diseases 71(Suppl 3): 674.2-674, 2013

Maintenance therapy with mycophenolate mofetil for children with severe lupus nephritis after low-dose intravenous cyclophosphamide regimen. Pediatric Nephrology 23(10): 1877-1882, 2008

Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis. Netherlands Journal of Medicine 72(9): 481-490, 2016

Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?. Clinical and Experimental Nephrology 14(3): 214-221, 2010

Tacrolimus versus mycophenolate mofetil for induction treatment of severe lupus nephritis: A randomized controlled trial. 2007

Is mycophenolate mofetil (MMF) better than intravenous cyclophosphamide for induction treatment of lupus nephritis?. Nefrologia 29(6 Suppl): 40-42, 2009

Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial. Bmc Nephrology 19(1): 175-175, 2018

Comparison of mycophenolate mofetil vs cyclophosphamide pulse therapy in the induction treatment of severe diffuse proliferative lupus nephritis in Chinese population. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 89A-90A, September, 2000

Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs 72(11): 1521-1533, 2012

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. American Journal of Kidney Diseases 32(2): 318-322, 1998

Maintenance therapy for proliferative forms of lupus nephritis A randomized clinical trial comparing quarterly intravenous cyclophosphamide versus oral mycophenolate mofetil or azathioprine. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 15A, September, 2002

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrology, Dialysis, Transplantation 22(7): 1933-1942, 2007

Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrology, Dialysis, Transplantation 27(4): 1467-1472, 2012